Mereo BioPharma Group plc (F:MAH0) — Market Cap & Net Worth
Market Cap & Net Worth: Mereo BioPharma Group plc (MAH0)
Mereo BioPharma Group plc (F:MAH0) has a market capitalization of $40.19 Million (€34.37 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #22669 globally and #1995 in its home market, demonstrating a -20.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mereo BioPharma Group plc's stock price €0.22 by its total outstanding shares 159131701 (159.13 Million). Analyse MAH0 operating cash flow to see how efficiently the company converts income to cash.
Mereo BioPharma Group plc Market Cap History: 2019 to 2026
Mereo BioPharma Group plc's market capitalization history from 2019 to 2026. Data shows change from $498.59 Million to $40.19 Million (-34.35% CAGR).
Mereo BioPharma Group plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mereo BioPharma Group plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
37.95x
Mereo BioPharma Group plc's market cap is 37.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $253.02 Million | $36.46 Million | $12.72 Million | 6.94x | 19.88x |
| 2023 | $379.53 Million | $10.00 Million | -$29.47 Million | 37.95x | N/A |
Competitor Companies of MAH0 by Market Capitalization
Companies near Mereo BioPharma Group plc in the global market cap rankings as of May 5, 2026.
Key companies related to Mereo BioPharma Group plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mereo BioPharma Group plc Historical Marketcap From 2019 to 2026
Between 2019 and today, Mereo BioPharma Group plc's market cap moved from $498.59 Million to $ 40.19 Million, with a yearly change of -34.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €40.19 Million | -88.54% |
| 2025 | €350.69 Million | -45.83% |
| 2024 | €647.43 Million | +70.59% |
| 2023 | €379.53 Million | +277.78% |
| 2022 | €100.46 Million | -60.29% |
| 2021 | €253.02 Million | -51.77% |
| 2020 | €524.64 Million | +5.22% |
| 2019 | €498.59 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Mereo BioPharma Group plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.19 Million USD |
| MoneyControl | $40.19 Million USD |
| MarketWatch | $40.19 Million USD |
| marketcap.company | $40.19 Million USD |
| Reuters | $40.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more